Graph Therapeutics Secures $3.1 Million to Revolutionize Immunological Drug Discovery Using AI

Graph Therapeutics, a pioneering techbio startup, has secured $3.1 million in a pre-seed funding round aimed at revolutionizing immunological drug discovery through artificial intelligence. The round was co-led by Merantix Capital and SquareOne, with participation from NAVEC Investment Management and strategic angel investors, including Mehdi Ghissassi via the Atomico Angel Program.

Founded by CEO Gregory Vladimer, an experienced entrepreneur with a background in immunology, Graph Therapeutics seeks to address the complexities of immune-mediated diseases by leveraging AI and precision medicine tools. Vladimer previously co-founded Allcyte, a company focused on precision oncology, which was acquired by Exscientia in 2021.

Graph Therapeutics operates at the initial stages of the drug discovery process, focusing on identifying novel targets—molecular areas in diseases where drugs could have the most beneficial effect. Through multimodal perturbation modeling, the company studies diseases comprehensively at clinical, molecular, and genetic levels, both at baseline and under various conditions.

The company’s approach involves integrating advanced disease modeling and high-quality data to enhance decision-making throughout the drug discovery and development pipeline. This spans from initial target discovery through pre-clinical work, including identifying patient enrichment strategies for trials. The ultimate goal is to ensure that the right patients receive the drugs being developed or supported.

Vladimer emphasizes the importance of a patient-centric approach, stating that if Graph Therapeutics succeeds in its mission, patients shouldn’t notice the technological advances—they’ll simply experience better outcomes. He envisions AI being thoughtfully integrated at key decision points throughout the drug discovery process, always with the patient’s needs as the guiding principle.

The $3.1 million funding will enable Graph Therapeutics to expand its team, enhance its AI-driven platform, and accelerate its research and development efforts. The company plans to continue building its operations in Europe, tapping into the region’s rich pool of scientific talent and supportive investment environment.

With this infusion of capital, Graph Therapeutics is poised to make significant strides in the field of immunological drug discovery, aiming to bring more effective and targeted treatments to patients suffering from complex immune-related diseases.